These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31666279)

  • 1. The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence.
    Chandrasekar AP; Cummins NW; Badley AD
    Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31666279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
    Xing S; Bullen CK; Shroff NS; Shan L; Yang HC; Manucci JL; Bhat S; Zhang H; Margolick JB; Quinn TC; Margolis DM; Siliciano JD; Siliciano RF
    J Virol; 2011 Jun; 85(12):6060-4. PubMed ID: 21471244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
    Shan L; Siliciano RF
    Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Block-And-Lock: New Horizons for a Cure for HIV-1.
    Moranguinho I; Valente ST
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding a cure for human immunodeficiency virus-1 infection.
    Blankson JN; Siliciano JD; Siliciano RF
    Infect Dis Clin North Am; 2014 Dec; 28(4):633-50. PubMed ID: 25277513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broad drug arsenal to attack a strenuous latent HIV reservoir.
    Stoszko M; Ne E; Abner E; Mahmoudi T
    Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime, shock and kill: BCL-2 inhibition for HIV cure.
    Chandrasekar AP; Badley AD
    Front Immunol; 2022; 13():1033609. PubMed ID: 36341439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
    Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
    Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naive CD4+ T lymphocytes express high levels of Bcl-2 after highly active antiretroviral therapy for HIV infection.
    Airò P; Torti C; Uccelli MC; Malacarne F; Palvarini L; Carosi G; Castelli F
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1805-7. PubMed ID: 11118066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.
    Deng K; Pertea M; Rongvaux A; Wang L; Durand CM; Ghiaur G; Lai J; McHugh HL; Hao H; Zhang H; Margolick JB; Gurer C; Murphy AJ; Valenzuela DM; Yancopoulos GD; Deeks SG; Strowig T; Kumar P; Siliciano JD; Salzberg SL; Flavell RA; Shan L; Siliciano RF
    Nature; 2015 Jan; 517(7534):381-5. PubMed ID: 25561180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
    Yang HC; Xing S; Shan L; O'Connell K; Dinoso J; Shen A; Zhou Y; Shrum CK; Han Y; Liu JO; Zhang H; Margolick JB; Siliciano RF
    J Clin Invest; 2009 Nov; 119(11):3473-86. PubMed ID: 19805909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
    Darcis G; Berkhout B; Pasternak AO
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
    Pohlmeyer CW; Walker-Sperling VE; Blankson JN
    Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
    [No Abstract]   [Full Text] [Related]  

  • 18. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
    Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
    PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.
    Reece MD; Song C; Hancock SC; Pereira Ribeiro S; Kulpa DA; Gavegnano C
    Front Immunol; 2022; 13():1033672. PubMed ID: 36569952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latency reversal and viral clearance to cure HIV-1.
    Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
    Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.